Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Cardiovascular comorbidities as predictors for severe COVID-19 infection or death

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Significant regional variation in use of implantable cardioverter-defibrillators in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of impaired cardiac conduction after alcohol septal ablation on clinical outcomes: Insights from the Euro-ASA registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Left ventricular myocardial crypts: morphological patterns and prognostic implications

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Left ventricular trabeculation and major adverse cardiovascular events: the Copenhagen General Population Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Matthew Phelps
  • Daniel Mølager Christensen
  • Thomas Gerds
  • Emil Fosbøl
  • Christian Torp-Pedersen
  • Morten Schou
  • Lars Køber
  • Kristian Kragholm
  • Charlotte Andersson
  • Tor Biering-Sørensen
  • Helle Collatz Christensen
  • Mikkel Porsborg Andersen
  • Gunnar Gislason
View graph of relations

BACKGROUND: Pre-existing cardiovascular diseases (CVDs) have been proposed to identify patients at higher risk of adverse COVID-19 outcomes, but existing evidence is conflicting. Thus, it is unclear whether pre-existing CVDs are independently important predictors for severe COVID-19.

METHODS AND RESULTS: In a nationwide Danish cohort of hospital-screened COVID-19 patients aged > =40, we investigated if pre-existing CVDs predict the 30-day risk of (1) composite outcome of severe COVID-19 and (2) all-cause mortality. We estimated 30-day risks using a Cox regression model including age, sex, each CVD comorbidity, COPD-asthma, diabetes, and chronic kidney disease. To illustrate CVD comorbidities' importance, we evaluated the predicted risks of death and severe infection, for each sex, along ages 40 - 85. 4,090 COVID-19 hospital-screened patients were observed as of August 26, 2020; 22.1% had ≥ 1 CVD, 23.7% had severe infection within 30 days and 12.6% died. Predicted risks of both outcomes at age 75 among men with single CVD comorbidities did not differ in clinically meaningful amounts compared to men with no comorbidities risks for the composite outcome of severe infection; women with heart failure (28.2%; 95% CI 21.1%-37.0%) or atrial fibrillation (30.0%; 95% CI: 24.2%-36.9%) showed modest increases compared to women with no comorbidities (24.0%; 95% CI: 21.4%-26.9%).

CONCLUSIONS: The results showing only modest effects of CVDs on increased risks of poor COVID-19 outcomes are important in allowing public health authorities and clinicians to provide more tailored guidance to cardiovascular patients, who have heretofore been grouped together as high-risk due to their disease status.

Original languageEnglish
JournalEuropean heart journal. Quality of care & clinical outcomes
ISSN2058-5225
DOIs
Publication statusE-pub ahead of print - 27 Oct 2020

ID: 61116592